The frequency and clinical significance of antibodies to soluble liver antigen/liver pancreas in autoimmune hepatitis: a prospective single-center study

Osman Yüksekyayla,Nabi Kina,Arjen Ulaba,Mehmet Emin Ergün,Ersin Batibay,Cem Şimşek,Fadile Yildiz Zeyrek,Staffan Wahlin,Cumali Efe
DOI: https://doi.org/10.1097/meg.0000000000002747
2024-04-01
European Journal of Gastroenterology & Hepatology
Abstract:Background and aims Soluble liver antigen/liver pancreas antibodies (anti-SLA/LP) are specific markers for autoimmune hepatitis (AIH) that have been associated with a distinct clinical phenotype and a more aggressive form of AIH. We prospectively evaluated the frequency and clinical significance of anti-SLA/LP in Turkish patients with AIH. Material and methods We prospectively included patients diagnosed with AIH between January 2018 and May 2023. Autoantibodies were detected using by immunofluorescence and immunoblot. Results We included 61 (80%, female) AIH patients with a median age of 31 years (15–78) at the time of diagnosis. Anti-SLA/LP was detected in 20% (n = 12) of the patients. Baseline characteristics, treatment responses and outcomes were similar among anti-SLA/LP-positive and anti-SLA/LP-negative AIH patients. Anti-SLA/LP-positive patients had significantly higher biochemical response rates after 4 weeks (100 vs. 67%, P = 0.027), 3 months (100 vs. 39%, P
gastroenterology & hepatology
What problem does this paper attempt to address?